AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Trial Identifier: D7405C00001
Sponsor: AstraZeneca
NCTID:: NCT06137118
Start Date: December 2023
Primary Completion Date: January 2026
Study Completion Date: February 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H4A 3J1
CA, QC Montreal, QC, CA, H3T1C5
CN Changsha, CN, 410008
CN Chengdu, CN, 610041
CN Guangzhou, CN, 510060
CN Hangzhou, CN, 310003
CN Nanjing, CN, 210008
CN Nanjing, CN, 210009
CN Suzhou, CN, 215006
CN Zhengzhou, CN, 450008
DE Essen, DE, 45147
DE Frankfurt A. Main, DE, 60590
DE Freiburg, DE, 79106
DE Halle, DE, 6120
DE Hamburg, DE, 20246
DE Köln, DE, 50937
DE Muenchen, DE, D-81377
DE Münster, DE, 48149
DE Würzburg, DE, 97080
ES Barcelona, ES, 08035
ES Madrid, ES, 28025
ES Madrid, ES, 28046
ES Valencia, ES, 46026
FR Marseille, FR, 13009
FR Nantes, FR, 44000
FR Paris, FR, 75019
FR Pierre Bénite, FR, 69495
GB London, GB, EC1A 7BE
GB Manchester, GB, M20 4BX
IT Bologna, IT, 40138
IT Monza, IT, 20900
IT ROMA, IT, 00165
KR Seoul, KR, 06351
KR Seoul, KR, 03722
KR Seoul, KR, 6591
KR Seoul, KR, 03080
TW Kaohsiung City, TW, 833401
TW Taichung, TW, 40705
TW Tainan City, TW, 70403
TW Taipei, TW, 10002
US, AL Birmingham, AL, US, 35233
US, CA Duarte, CA, US, 91010
US, CA Los Angeles, CA, US, 90048
US, CA Palo Alto, CA, US, 94304
US, FL Tampa, FL, US, 33612
US, IL Chicago, IL, US, 60637
US, NY New York, NY, US, 10016
US, TX Houston, TX, US, 77030
US, VA Richmond, VA, US, 23298
US, WA Seattle, WA, US, 98109
US, WI Milwaukee, WI, US, 53226